Long title
A phase IIa partial blind, placebo-controlled clinical trial to evaluate the safety and immunogenicity of the Ad5-EBOV in healthy adults aged between 18 and 60 years in Belgium.
Date receipt dossier
EU record number
EBOVEU001
EudraCT number
2018-003912-29
Company / Sponsor
Bejing Institute of Biotechnology, CanSino Biologics Inc,
Phase
IIa
Treated organism
Humans
Indication category
Infectious disease
Disease
Ebola virus infection
Therapeutic approach
Prevention
Genetic modification
Recombinant Adenoviral vector serotype 5 expressing the envelop glycoprotein from Ebola virus (Zaïre-Makona)
Method of transfer of nucleic acid of interest
Not applicable
Administered biological material
Recombinant Adenoviral vector serotype 5 expressing the envelop glycoprotein from Ebola virus (Zaïre-Makona)
Route of administration
Intradermal & Intramuscular
Locations in Belgium
U Antwerpen
Type of procedure
Contained use only
Current status
Authorized
Pharmaceutical study code
Ad5-EBOV